© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
September 27, 2021
Treatment with neoadjuvant cisplatin and pemetrexed plus atezolizumab for pleural mesothelioma found to be safe in trial.
September 20, 2021
There are 4 essential epidermal growth factor receptor-mutant non-small cell lung cancer subgroups, according to new research results.
September 16, 2021
The FDA approved Exkivity to treat non-small cell lung cancer along with Thermo Fisher Scientific’s Oncomine DX Target Test, which is intended to be a companion diagnostic for the treatment.
Dr. Jason Liu and his colleagues hoped to assess the use of maintenance durvalumab based on patient and physician characteristics among individuals with stage 3 NSCLC in the United States.
Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.
September 15, 2021
The regimen with chemotherapy continues to show longer rates at 9 months compared with 4.9 months for chemotherapy and the placebo.
Stereotactic ablative radiotherapy has similar overall and progression-free survival rates.
September 14, 2021
Individuals who had depression or stress in a hospital in Mexico were also 4.5 and 3.18 times more likely, respectively, to experience delays in treatment.
September 10, 2021
New artificial intelligence tool can identify tumors at a 97% rate, a year before other methods can diagnose it.
Results from POSEIDON, a randomized open label, phase 3 trial, showed that patients administered 5 cycles of tremelimumab plus durvalumab and chemotherapy over 16 weeks experienced a 23% reduction in the risk of death compared with various chemotherapy options.